<div class="entities" style="line-height: 2.5; direction: ltr">de pointes 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventricular tachycardia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 during low dose intermittent 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dobutamine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
treatment in a patient with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dilated cardiomyopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    congestive heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">The authors describe the case of a 56 - year - old woman with chronic severe 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heart failure
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 secondary to 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dilated cardiomyopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 and absence of significant 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventricular arrhythmias
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 who developed 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    QT prolongation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    torsade de pointes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventricular tachycardia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 during one cycle of intermittent low dose ( 2 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">5 mcg / kg per min ) 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dobutamine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
.</div>

<div class="entities" style="line-height: 2.5; direction: ltr">This report of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    torsade de pointes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ventricular tachycardia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 during intermittent 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dobutamine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
supports the hypothesis that unpredictable fatal 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    arrhythmias 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
may occur even with low doses and in patients with no history of significant 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rhythm disturbances
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">The mechanisms of proarrhythmic effects of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Dubutamine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
are discussed .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Positive skin tests in late reactions to radiographic 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    contrast media
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">In the last few years delayed reactions several hours after the injection of radiographic and contrast materials ( PRC ) have been described with increasing frequency .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">The authors report two observations on patients with delayed reactions in whom intradermoreactions ( IDR ) and patch tests to a series of ionic and non ionic 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PRC 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
were studied .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">After angiography by the venous route in patient n degree 1 a biphasic reaction with an immediate reaction ( 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dyspnea 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>

<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    loss of consciousness
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 ) and delayed macro - 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    papular 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>

<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rash 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
appeared whilst patient n degree 2 developed a generalised sensation of heat persistent 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pain 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
at the site of injection immediately and a generalised macro - papular reaction after 24 hours .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">The skin tests revealed positive delayed reactions of 24 hours and 48 hours by IDR and patch tests to only some PRC with common chains in their structures .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">The positive skin tests are in favour of immunological reactions and may help in diagnosis of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    allergy 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
in the patients .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Risk of transient 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperammonemic encephalopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 in 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
patients who received continuous infusion of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    5 - fluorouracil
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 with the complication of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dehydration 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infection 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
.</div>

<div class="entities" style="line-height: 2.5; direction: ltr">From 1986 to 1998 29 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cancer 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
patients who had 32 episodes of transient 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperammonemic encephalopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 related to continuous infusion of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    5 - fluorouracil
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 ( 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    5 - FU
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 ) were identified .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">None of the patients had decompensated 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    liver disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Onset of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperammonemic encephalopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 varied from 0 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">5 to 5 days ( mean : 2 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">6 + / - 1 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">3 days ) after the initiation of chemotherapy .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Plasma 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ammonium 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
level ranged from 248 to 2387 microg % ( mean : 626 + / - 431 microg % ) .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Among the 32 episodes 26 ( 81 % ) had various degrees of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    azotemia 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
18 ( 56 % ) occurred during 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bacterial infections
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 and 14 ( 44 % ) without 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    infection 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
occurred during periods of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dehydration 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
.</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Higher plasma 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ammonium 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
levels and more rapid onset of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperammonemia 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
were seen in 18 patients with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bacterial infections
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 ( p = 0 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">003 and 0 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">0006 respectively ) and in nine patients receiving high daily doses ( 2600 or 1800 mg / m2 ) of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    5 - FU
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 ( p = 0 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">0001 and &lt; 0 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">0001 respectively ) .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">In 25 out of 32 episodes ( 78 % ) plasma 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ammonium 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
levels and mental status returned to normal within 2 days after adequate management .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">In conclusion 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperammonemic encephalopathy
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 can occur in patients receiving continuous infusion of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    5 - FU
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Azotemia 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>

<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    body fluid insufficiency
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bacterial infections
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 were frequently found in these patients .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">It is therefore important to recognize this condition in patients receiving continuous infusion of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    5 - FU
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">The effects of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    quinine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    4 - aminopyridine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 on conditioned place preference and changes in motor activity induced by 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morphine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
in rats .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">1 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">The effects of two unselective 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    potassium 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
( 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
( + ) - ) channel blockers 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    quinine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
( 12 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">5 25 and 50 mg / kg ) and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    4 - aminopyridine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 ( 1 and 2 mg / kg ) on conditioned place preference and biphasic changes in motor activity induced by 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morphine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
( 10 mg / kg ) were tested in Wistar rats .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Quinine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
is known to block voltage - 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    calcium 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ATP 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- sensitive 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
( + ) - channels while 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    4 - aminopyridine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 is known to block voltage - sensitive 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
( + ) - channels .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">2 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">In the counterbalanced method 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    quinine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
attenuated 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morphine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- induced place preference whereas 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    4 - aminopyridine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 was ineffective .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">In the motor activity test measured with an Animex - activity meter neither of the 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
( + ) - channel blockers affected 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morphine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- induced 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoactivity 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
but both 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
( + ) - channel blockers prevented 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morphine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- induced secondary 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperactivity 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
.</div>

<div class="entities" style="line-height: 2.5; direction: ltr">3 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">These results suggest the involvement of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    quinine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- sensitive but not 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    4 - aminopyridine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 - sensitive 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
( + ) - channels in 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morphine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
reward .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">It is also suggested that the blockade of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
( + ) - channels sensitive to these blockers is not sufficient to prevent 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morphine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- induced 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypoactivity 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
whereas 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    morphine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- induced 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperactivity 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
seems to be connected to both 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    quinine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    4 - aminopyridine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 - sensitive 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    K 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
( + ) - channels .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nociceptin / orphanin FQ
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocistatin 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
on 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    learning and memory impairment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 induced by 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    scopolamine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
in mice .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">1 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nociceptin 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
also known as 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    orphanin FQ
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 is an endogenous ligand for the orphan opioid receptor - like receptor 1 ( ORL1 ) and involves in various functions in the central nervous system ( CNS ) .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">On the other hand 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocistatin 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
is recently isolated from the same precursor as 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nociceptin 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
and blocks 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nociceptin 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- induced 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    allodynia 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hyperalgesia 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
.</div>

<div class="entities" style="line-height: 2.5; direction: ltr">2 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Although 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ORL1 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
receptors which display a high degree of sequence homology with classical opioid receptors are abundant in the hippocampus little is known regarding their role in learning and memory .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">3 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">The present study was designed to investigate whether 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nociceptin 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
/ 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    orphanin FQ
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocistatin 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
could modulate 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    impairment of learning and memory
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 induced by 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    scopolamine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
a muscarinic cholinergic receptor antagonist using spontaneous alternation of Y - maze and step - down type passive avoidance tasks in mice .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">4 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">While 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocistatin 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
( 0 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">5 - 5 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">0 nmol mouse - 1 i .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">c .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">v .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">) administered 30 min before spontaneous alternation performance or the training session of the passive avoidance task had no effect on spontaneous alternation or passive avoidance behaviours a lower per cent alternation and shorter median step - down latency in the retention test were obtained in 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nociceptin 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
( 1 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">5 and / or 5 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">0 nmol mouse - 1 i .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">c .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">v .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">) - treated normal mice .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">5 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Administration of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocistatin 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
( 1 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">5 and / or 5 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">0 nmol mouse - 1 i .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">c .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">v .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">) 30 min before spontaneous alternation performance or the training session of the passive avoidance task attenuated the 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    scopolamine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- induced impairment of spontaneous alternation and passive avoidance behaviours .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">6 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">These results indicated that 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nocistatin 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
a new biologically active peptide ameliorates impairments of spontaneous alternation and passive avoidance induced by 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    scopolamine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
and suggested that these peptides play opposite roles in learning and memory .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Meloxicam 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- induced 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    liver toxicity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">We report the case of a female patient with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    rheumatoid arthritis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 who developed acute cytolytic 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hepatitis 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
due to 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    meloxicam 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
.</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Recently introduced in Belgium 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    meloxicam 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
is the first nonsteroidal antiinflammatory drug with selective action on the inducible form of cyclooxygenase 2 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">The acute cytolytic 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hepatitis 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
occurred rapidly after 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    meloxicam 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
administration and was associated with the development of antinuclear antibodies suggesting a 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersensitivity 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
mechanism .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">This first case of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    meloxicam 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
related 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    liver toxicity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 demonstrates the potential of this drug to induce 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hepatic damage
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Induction of apoptosis by 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    remoxipride 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
metabolites in HL60 and CD34 + / CD19 - human bone marrow progenitor cells : potential relevance to 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    remoxipride 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- induced 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aplastic anemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">The antipsychotic agent 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    remoxipride [ ( S ) - ( - ) - 3 - bromo - N - [ ( 1 - ethyl - 2 - pyrrolidinyl ) methyl ] - 2 6 - dimethoxybenz amide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 ] has been associated with acquired 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aplastic anemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">We have examined the ability of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    remoxipride 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
three 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pyrrolidine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
ring metabolites and five aromatic ring metabolites of the parent compound to induce apoptosis in HL60 cells and human bone marrow progenitor ( HBMP ) cells .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Cells were treated for 0 - 24 h with each compound ( 0 - 200 microM ) .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Apoptosis was assessed by fluorescence microscopy in Hoechst 33342 - and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    propidium iodide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 stained cell samples .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Results were confirmed by determination of internucleosomal DNA fragmentation using gel electrophoresis for HL60 cell samples and terminal 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    deoxynucleotidyl 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
transferase assay in HBMP cells .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">The 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    catechol 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hydroquinone 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
metabolites 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NCQ436 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NCQ344 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
induced apoptosis in HL60 and HBMP cells in a time - and concentration dependent manner while the 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    phenols 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>

<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NCR181 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>

<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    FLA873 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    FLA797 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
and the derivatives formed by oxidation of the 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pyrrolidine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
ring FLA838 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NCM001 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
and NCL118 had no effect .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">No 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    necrosis 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
was observed in cells treated with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NCQ436 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
but 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NCQ344 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
had a biphasic effect in both cell types inducing apoptosis at lower concentrations and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    necrosis 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
at higher concentrations .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">These data show that the 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    catechol 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hydroquinone 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
metabolites of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    remoxipride 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
have direct toxic effects in HL60 and HBMP cells leading to apoptosis while the 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    phenol 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
metabolites were inactive .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Similarly 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    benzene 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- derived 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    catechol 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hydroquinone 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
but not 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    phenol 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
induce apoptosis in HBMP cells [ Moran et al .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Mol .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Pharmacol .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">50 ( 1996 ) 610 - 615 ] .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">We propose that 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    remoxipride 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    benzene 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
may induce 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aplastic anemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 via production of similar reactive metabolites and that the ability of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NCQ436 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NCQ344 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    aplastic anemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 that has been associated with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    remoxipride 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
.</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Synthesis and preliminary pharmacological investigations of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    1 - ( 1 2 - dihydro - 2 - acenaphthylenyl ) piperazine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 derivatives as potential atypical antipsychotic agents in mice .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">In research towards the development of new atypical antipsychotic agents one strategy is that the dopaminergic system can be modulated through manipulation of the serotonergic system .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">The synthesis and preliminary pharmacological evaluation of a series of potential atypical antipsychotic agents based on the structure of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    1 - ( 1 2 - dihydro - 2 - acenaphthylenyl ) piperazine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 ( 7 ) is described .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Compound 7e 5 - { 2 - [ 4 - ( 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    1 2 - dihydro - 2 - acenaphthylenyl ) piperazinyl ] ethyl } - 2 3 - dihy dro - 1H - indol - 2 -
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 one from this series showed significant affinities at the 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    5 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- HT1A and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    5 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- HT2A receptors and moderate affinity at the 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    D2 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
receptor .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    7e 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
exhibits a high reversal of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    catalepsy 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
induced by 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    haloperidol 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
indicating its atypical antipsychotic nature .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Sub - chronic inhibition of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nitric - oxide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 synthesis modifies 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    haloperidol 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- induced 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    catalepsy 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
and the number of NADPH - diaphorase neurons in mice .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">RATIONALE : 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NG - nitro - L - arginine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 ( 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    L - NOARG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 ) an inhibitor of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nitric - oxide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 synthase ( NOS ) induces 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    catalepsy 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
in mice .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">This effect undergoes rapid tolerance showing a significant decrease after 2 days of sub - chronic 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    L - NOARG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 treatment .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nitric oxide
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 ( 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NO 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
) has been shown to influence dopaminergic neurotransmission in the striatum .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Neuroleptic drugs such as 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    haloperidol 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
which block 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dopamine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
receptors also cause 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    catalepsy 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
in rodents .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">OBJECTIVES : To investigate the effects of subchronic 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    L - NOARG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 treatment in 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    haloperidol 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- induced 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    catalepsy 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
and the number of NOS neurons in areas related to motor control .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">METHODS : Male albino Swiss mice were treated sub - chronically ( twice a day for 4 days ) with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    L - NOARG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 ( 40 mg / kg i .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">p .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">) or 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    haloperidol 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
( 1 mg / kg i .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">p .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">) .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Catalepsy was evaluated at the beginning and the end of the treatments .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Reduced 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nicotinamide adenine dinucleotide phosphate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 - diaphorase ( NADPH - d ) histochemistry was also employed to visualize NOS as an index of enzyme expression in mice brain regions related to motor control .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">RESULTS : 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    L - NOARG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 sub - chronic administration produced tolerance of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    L - NOARG
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 and of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    haloperidol 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- induced 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    catalepsy 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
.</div>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    It 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
also induced an increase in the number of NADPH - d - positive cells in the dorsal part of the caudate and accumbens nuclei compared with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    haloperidol 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
and in the pedunculopontine tegmental nucleus compared with saline .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">In contrast there was a decrease in NADPH - d neuron number in the substantia nigra pars compacta in both 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    haloperidol 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- treated and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    L 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- NOARG - treated animals .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">CONCLUSIONS : The results give further support to the hypothesis that NO plays a role in motor behavior control and suggest that it may take part in the synaptic changes produced by antipsychotic treatment .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Prolonged 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    left ventricular dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 occurs in patients with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    coronary artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 after both 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dobutamine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
and exercise induced 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial ischaemia
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">OBJECTIVE : To determine whether pharmacological stress leads to prolonged but reversible 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    left ventricular dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 in patients with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    coronary artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 similar to that seen after exercise .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">DESIGN : A randomised crossover study of recovery time of systolic and diastolic left ventricular function after exercise and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dobutamine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
induced 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ischaemia 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
.</div>

<div class="entities" style="line-height: 2.5; direction: ltr">SUBJECTS : 10 patients with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    stable angina
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 angiographically proven 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    coronary artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 and normal left ventricular function .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">INTERVENTIONS : Treadmill exercise and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dobutamine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
stress were performed on different days .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Quantitative assessment of systolic and diastolic left ventricular function was performed using transthoracic echocardiography at baseline and at regular intervals after each test .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">RESULTS : Both forms of stress led to prolonged but reversible 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    systolic and diastolic dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">There was no difference in the maximum double product ( p = 0 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">53 ) or ST 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    depression 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
( p = 0 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">63 ) with either form of stress .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">After exercise ejection fraction was reduced at 15 and 30 minutes compared with baseline ( mean ( SEM ) - 5 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">6 ( 1 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">5 ) % p &lt; 0 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">05 ; and - 6 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">1 ( 2 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">2 ) % p &lt; 0 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">01 ) and at 30 and 45 minutes after 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dobutamine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
( - 10 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">8 ( 1 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">8 ) % and - 5 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">5 ( 1 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">8 ) % both p &lt; 0 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">01 ) .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Regional analysis showed a reduction in the worst affected segment 15 and 30 minutes after exercise ( - 27 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">9 ( 7 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">2 ) % and - 28 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">6 ( 5 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">7 ) % both p &lt; 0 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">01 ) and at 30 minutes after 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dobutamine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
( - 32 ( 5 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">3 ) % p &lt; 0 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">01 ) .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">The isovolumic relaxation period was prolonged 45 minutes after each form of stress ( p &lt; 0 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">05 ) .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">CONCLUSIONS : In patients with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    coronary artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dobutamine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
induced 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ischaemia 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
results in prolonged reversible 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    left ventricular dysfunction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 presumed to be 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    myocardial stunning
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 similar to that seen after exercise .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Dobutamine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
induced 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ischaemia 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
could therefore be used to study the pathophysiology of this phenomenon further in patients with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    coronary artery disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Anorexigens 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 in the United States : results from the surveillance of North American 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">BACKGROUND : The use of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    appetite suppressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 in Europe has been associated with the development of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    primary pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 ( 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PPH 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
) .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Recently 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fenfluramine 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>

<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    appetite suppressants
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
 became widely used in the United States but were withdrawn in September 1997 because of concerns over adverse effects .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">MATERIALS AND METHODS : We conducted a prospective surveillance study on patients diagnosed with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 at 12 large referral centers in North America .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Data collected on patients seen from September 1 1996 to December 31 1997 included the cause of the 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 and its severity .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Patients with no identifiable cause of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 were classed as PPH .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">A history of drug exposure also was taken with special attention on the use of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    antidepressants 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
anorexigens and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    amphetamines 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
.</div>

<div class="entities" style="line-height: 2.5; direction: ltr">RESULTS : Five hundred seventy - nine patients were studied 205 with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PPH 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
and 374 with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 from other causes ( 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    secondary pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 [ 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SPH 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
] ) .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">The use of anorexigens was common in both groups .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">However of the medications surveyed only the 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fenfluramines 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
had a significant preferential association with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PPH 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
as compared with SPH ( adjusted odds ratio for use &gt; 6 months 7 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">5 ; 95 % confidence interval 1 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">7 to 32 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">4 ) .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">The association was stronger with longer duration of use when compared to shorter duration of use and was more pronounced in recent users than in remote users .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">An unexpectedly high ( 11 .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">4 % ) number of patients with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SPH 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
had used anorexigens .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">CONCLUSION : The magnitude of the association with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PPH 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
the increase of association with increasing duration of use and the specificity for 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fenfluramines 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
are consistent with previous studies indicating that 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    fenfluramines 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
are causally related to 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PPH 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
.</div>

<div class="entities" style="line-height: 2.5; direction: ltr">The high prevalence of anorexigen use in patients with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SPH 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
also raises the possibility that these drugs precipitate 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pulmonary hypertension
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
 in patients with underlying conditions associated with 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SPH 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
.</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Clinical aspects of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heparin 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
- induced 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    thrombocytopenia 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
and 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    thrombosis 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
and other side effects of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heparin 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
therapy .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Heparin 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
first used to prevent the clotting of blood in vitro has been clinically used to treat 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    thrombosis 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
for more than 50 years .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">Although several new anticoagulant drugs are in development 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heparin 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
remains the anticoagulant of choice to treat acute 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    thrombotic 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
episodes .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">The clinical effects of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heparin 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
are meritorious but side effects do exist .</div>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Bleeding 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease</span>
</mark>
is the primary untoward effect of 
<mark class="entity" style="background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    heparin 
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Chemical</span>
</mark>
.</div>
